Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Women's Heart Attack Research Program: Stress Ancillary Study

NCT02914483 · View on ClinicalTrials.gov ↗

Study Summary

The Women's HARP study is a multi-center study focusing on women with clinical presentation of myocardial infarction (MI). Women will complete stress questionnaires following presentation to the medical center with elevated cardiac enzymes and abnormal electrocardiograms (ECGs). 2 months following MI, participants will be screened for the Stress Ancillary Study and enrolled if an elevated level of perceived stress is reported. After completing baseline assessments, participants will be randomized to Enhanced Usual Care (EUC) or stress management for 8 weeks. Participants will be followed for 6 months.

Conditions Studied

Interventions

  • BEHAVIORAL Enhanced Usual Care
  • BEHAVIORAL Stress Management
  • DIAGNOSTIC_TEST Actigraph

Study Locations (14)

New York

  • NYU Winthrop — Mineola
  • NYU Langone Medical Center — New York
  • Columbia University Medical Center — New York

Pennsylvania

  • St. Luke's University Health Network — Bethlehem
  • University of Pittsburgh Medical Center — Pittsburgh

California

  • Cedars-Sinai Medical Center — Los Angeles

Florida

  • Univeristy of Florida — Gainesville

Georgia

  • Emory University — Atlanta

Maryland

  • Johns Hopkins Medical Center — Baltimore

New Hampshire

  • Dartmouth-Hitchcock — Lebanon

Ohio

  • Ohio State University Medical Center — Columbus

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2016-08-01
Est. Completion 2026-06-30
Phase NA

Sponsor

NYU Langone Health

1,204 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02914483

The ClinicalTrials.gov registry entry for NCT02914483 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,204 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Myocardial Infarction appearing as the primary indexed condition, and to 3 interventions — of which Enhanced Usual Care is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02914483 reports 14 study locations spanning 11 distinct geographic areas — top geographies include New York, Pennsylvania, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02914483 about?

NCT02914483 is a clinical study titled "Women's Heart Attack Research Program: Stress Ancillary Study". The Women's HARP study is a multi-center study focusing on women with clinical presentation of myocardial infarction (MI). Women will complete stress questionnaires following presentation to the medical center with elevated cardiac enzymes and abnormal electrocardiograms (ECGs). 2 months following M...

What is the current status of trial NCT02914483?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2016-08-01. Estimated completion is 2026-06-30.

What conditions does trial NCT02914483 study?

This clinical trial studies the following conditions: Myocardial Infarction. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02914483?

The interventions under investigation include: Enhanced Usual Care (BEHAVIORAL), Stress Management (BEHAVIORAL), Actigraph (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02914483?

This trial is sponsored by NYU Langone Health, which has 1,204 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02914483 being conducted?

This trial has 14 study locations across California, Florida, Georgia, Maryland, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial